A research aiming to develop a lipid nanoparticles (LNP) platform for treating oral squamous cell carcinoma (OSCC) using p53 mRNA was introduced on the 102nd Basic Session of the IADR, which was held along side the 53rd Annual Assembly of the American Affiliation for Dental, Oral, and Craniofacial Analysis and the forty eighth Annual Assembly of the Canadian Affiliation for Dental Analysis, on March 13-16, 2024, in New Orleans, LA, U.S..
The summary, “mRNA Lipid Nanoparticles for Subsequent-Era Oral Most cancers Tumor Suppressor Remedy” was introduced through the “AADOCR Hatton: Put up-doctoral” Poster Session that came about on Friday, March 15, 2024 at 3:45 p.m. Central Normal Time (UTC-6).
The research, by Marshall Scott Padilla of College of Pennsylvania, Philadelphia, U.S., formulated a library of LNPs with luciferase mRNA and examined in CAL-27 cells, a mannequin OSCC line. The LNPs have been additionally injected intravenously into C57BL/6 mice to look at their propensity for off-target liver transfection. The LNPs that had excessive luminescence in CAL-27 cells and low liver transfection progressed to the subsequent spherical of screening.
Then, the highest LNPs have been evaluated for transfection after intratumoral administration in a CAL-27 xenograft mannequin. E10i-494 demonstrated the very best tumor luminescence and was picked because the lead candidate. This LNP was then evaluated in an orthotopic CAL-27 murine mannequin. Lastly, the lead LNP was reformulated with p53 mRNA, and the tumor-suppress-mediated toxicity was evaluated in CAL-27 cells.
After two rounds of screening, the LNP E10i-494 demonstrated immense mRNA transfection in vitro and in two murine tumor fashions. Moreover, the LNP had low ranges of liver transfection, showcasing a promising security profile. Within the orthotopic mannequin, the LNP efficiently entered and transfected lymph nodes, which is important for stopping tumor metastasis. E10i-494 additionally demonstrated potent cell killing after being reformulated with p53 mRNA.
The research concluded that the primary LNP for the oral cavity has been optimized and its potential for p53-based OSCC remedy has been demonstrated.
Supplied by Worldwide Affiliation for Dental, Oral, and Craniofacial Analysis